Comparative proteomics of proliferative diabetic retinopathy in people with Type 2 diabetes highlights the role of inflammation, visual transduction, and extracellular matrix pathways.


Journal

Indian journal of ophthalmology
ISSN: 1998-3689
Titre abrégé: Indian J Ophthalmol
Pays: India
ID NLM: 0405376

Informations de publication

Date de publication:
08 2023
Historique:
medline: 3 8 2023
pubmed: 2 8 2023
entrez: 2 8 2023
Statut: ppublish

Résumé

To explore the vitreous humor proteome from type 2 diabetes subjects with proliferative diabetic retinopathy (PDR) in the Indian population. We performed mass spectrometry-based label-free quantitative analysis of vitreous proteome of PDR (n = 13) and idiopathic macular hole (IMH; control) subjects (n = 14). Nine samples of PDR and 10 samples of IMH were pooled as case and control, respectively, and compared. Four samples each of PDR and IMH were analyzed individually without pooling to validate the results of the pooled analysis. Comparative quantification was performed using Scaffold software which calculated the fold changes of differential expression. Bioinformatics analysis was performed using DAVID and STRING software. We identified 469 proteins in PDR and 517 proteins in IMH vitreous, with an overlap of 172 proteins. Also, 297 unique proteins were identified in PDR and 345 in IMH. In PDR vitreous, 37 proteins were upregulated (P < 0.05) and 19 proteins were downregulated compared to IMH. Protein distribution analysis clearly demonstrated a separation of protein expression in PDR and IMH. Significantly upregulated proteins included fibrinogen gamma chain, fibrinogen beta chain, and carbonic anhydrase 1 and downregulated proteins included alpha-1-antitrypsin, retinol-binding protein 3, neuroserpin, cystatin C, carboxypeptidase E and cathepsin-D. Diabetic retinopathy pathogenesis involves proteins which belong to inflammation, visual transduction, and extracellular matrix pathways. Validation-based experiments using enzyme-linked immunosorbent assay (ELISA) or western blotting are needed to establish cause and effect relationships of these proteins to the disease state, to develop them as biomarkers or drug molecules.

Identifiants

pubmed: 37530283
pii: IndianJOphthalmol_2023_71_8_3069_382651
doi: 10.4103/IJO.IJO_276_23
pmc: PMC10538831
doi:

Substances chimiques

Proteome 0
Fibrinogen 9001-32-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3069-3079

Déclaration de conflit d'intérêts

None

Références

Int J Med Sci. 2021 Jan 26;18(6):1390-1398
pubmed: 33628095
Exp Eye Res. 2013 Mar;108:110-9
pubmed: 23276812
Diabetologia. 2009 Dec;52(12):2633-41
pubmed: 19823802
BMC Ophthalmol. 2018 Jun 26;18(1):151
pubmed: 29940965
Nat Med. 2007 Feb;13(2):181-8
pubmed: 17259996
Diabetologia. 2007 Jun;50(6):1294-303
pubmed: 17380318
Br J Ophthalmol. 2009 Apr;93(4):429-34
pubmed: 19091856
Transl Vis Sci Technol. 2018 Sep 26;7(5):12
pubmed: 30271679
Diabet Med. 2013 Jun;30(6):640-50
pubmed: 23205608
Ophthalmology. 2009 Feb;116(2):311-8
pubmed: 19084275
J Diabetes Res. 2015;2015:319692
pubmed: 26075282
Arch Ophthalmol. 2008 Aug;126(8):1076-81
pubmed: 18695102
FEBS J. 2013 Nov;280(22):5668-81
pubmed: 23763694
Nature. 2013 Jul 18;499(7458):306-11
pubmed: 23868260
Front Immunol. 2020 Feb 11;11:154
pubmed: 32117292
Vision Res. 2017 Oct;139:153-160
pubmed: 28438679
Exp Eye Res. 2018 Sep;174:29-39
pubmed: 29778740
Diabetes Care. 2022 Sep 1;45(9):2159-2162
pubmed: 35852358
Int J Mol Sci. 2020 May 15;21(10):
pubmed: 32429045
Eye (Lond). 1992;6 ( Pt 6):553-5
pubmed: 1289129
J Proteome Res. 2015 Dec 4;14(12):5131-43
pubmed: 26490944
PLoS One. 2015 May 28;10(5):e0127567
pubmed: 26020955
Diabetes. 2020 Nov;69(11):2467-2480
pubmed: 32887674
FASEB J. 2022 Oct;36(10):e22531
pubmed: 36063130
J Ophthalmol. 2018 Apr 19;2018:7397610
pubmed: 29850212
Front Oncol. 2018 May 04;8:145
pubmed: 29780748
Microvasc Res. 2023 Jul;148:104510
pubmed: 36822364
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Aug 25;776(1):89-100
pubmed: 12127329
Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2328-33
pubmed: 15980218
Biol Res. 2014 Nov 18;47:58
pubmed: 25723058
Sci Transl Med. 2019 Jul 3;11(499):
pubmed: 31270273
PLoS One. 2013 Nov 29;8(11):e82140
pubmed: 24312404
Clin Proteomics. 2018 Mar 09;15:12
pubmed: 29541006
Sci Rep. 2017 Aug 21;7(1):8412
pubmed: 28827627
Front Neurosci. 2019 Mar 19;13:243
pubmed: 30941009
FASEB J. 2016 Apr;30(4):1670-82
pubmed: 26718887
Proteomics Insights. 2017 Mar 15;8:1178641816686078
pubmed: 28469465
Cold Spring Harb Protoc. 2020 Apr 1;2020(4):102269
pubmed: 32238597
Exp Eye Res. 2005 Aug;81(2):176-82
pubmed: 16080911
Biochem Biophys Res Commun. 2009 Dec 18;390(3):368-71
pubmed: 19833100
J Biol Chem. 2012 Jul 27;287(31):25869-80
pubmed: 22648458
Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5783-5791
pubmed: 29117316
Proteomics. 2007 Nov;7(22):4203-15
pubmed: 17955474
Exp Eye Res. 2015 Apr;133:58-68
pubmed: 25819455
J Proteome Res. 2008 Jun;7(6):2516-25
pubmed: 18433156
Invest Ophthalmol Vis Sci. 2005 Jan;46(1):349-57
pubmed: 15623795
Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD31-AMD40
pubmed: 30025106
ASN Neuro. 2022 Jan-Dec;14:17590914221131446
pubmed: 36221892
Curr Eye Res. 2006 Mar;31(3):231-40
pubmed: 16531280
Ann Clin Transl Neurol. 2015 Jul;2(7):722-38
pubmed: 26273685
Trends Endocrinol Metab. 2014 Jan;25(1):23-33
pubmed: 24183659
Mol Cell Proteomics. 2003 Nov;2(11):1177-87
pubmed: 12975481
JAMA Ophthalmol. 2022 Jun 1;140(6):587-597
pubmed: 35511139
J Neurochem. 2005 Dec;95(5):1351-62
pubmed: 16219026
Cochrane Database Syst Rev. 2018 Oct 16;10:CD007419
pubmed: 30325017
J Proteomics. 2015 Feb 06;115:23-35
pubmed: 25497218
Ophthalmol Retina. 2018 Jun;2(6):558-566
pubmed: 31047609
Biomed Phys Eng Express. 2023 Feb 09;:
pubmed: 36758224
BMJ Open Diabetes Res Care. 2014 Jun 06;2(1):e000005
pubmed: 25452856

Auteurs

Sagnik Sen (S)

Department of Retina and Vitreous Services, Aravind Eye Hospital; Department of Proteomics, Aravind Medical Research Foundation, Madurai, Tamil Nadu, India.

Prithviraj Udaya (P)

Department of Retina and Vitreous Services, Aravind Eye Hospital; Department of Proteomics, Aravind Medical Research Foundation, Madurai, Tamil Nadu, India.

Jayapal Jeya Maheshwari (J)

Department of Proteomics, Aravind Medical Research Foundation, Madurai, Tamil Nadu, India.

Piyush Kohli (P)

Department of Retina and Vitreous Services, Aravind Eye Hospital, Madurai, Tamil Nadu, India.

Haemoglobin Parida (H)

Department of Retina and Vitreous Services, Aravind Eye Hospital, Madurai, Tamil Nadu, India.

Naresh Babu Kannan (NB)

Department of Retina and Vitreous Services, Aravind Eye Hospital, Madurai, Tamil Nadu, India.

Kim Ramasamy (K)

Department of Retina and Vitreous Services, Aravind Eye Hospital, Madurai, Tamil Nadu, India.

Kuppamuthu Dharmalingam (K)

Department of Proteomics, Aravind Medical Research Foundation, Madurai, Tamil Nadu, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH